Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report.
The authors report the clinicopathological findings in a patient in whom levodopa-responsive parkinsonism developed at 45 years of age. The patient experienced asymmetrical onset of symptoms, sustained benefit from levodopa, and motor fluctuations and dyskinesias, but there were no prominent autonomic, cerebellar, or pyramidal signs. He was diagnosed clinically with Parkinson disease (PD) and underwent bilateral subthalamic nucleus deep brain stimulation (DBS) surgery 9 years after symptom onset. He did not respond to stimulation or medication postoperatively, however, and died 12 weeks after surgery of repeated aspiration pneumonias. Postmortem examination revealed neuron loss in the substantia nigra and basal ganglia, and numerous alpha-synuclein-positive glial cytoplasmic inclusions in the subcortical nuclei, cerebellum, and brainstem, findings that established a neuropathological diagnosis of multiple system atrophy (MSA). Furthermore, there was an atypical and robust inflammatory reaction, as well as numerous glial cytoplasmic inclusions surrounding both DBS electrode termination sites. The authors speculate that the presence of alpha-synuclein in the striatum, combined with the inflammation surrounding the electrodes, contributed to the ineffectiveness of stimulation and dopaminergic medications postoperatively. This case demonstrates the ineffectiveness of DBS in MSA, even when the patient is responsive to levodopa, and emphasizes the need for diagnostic modalities that can be used to distinguish PD from MSA and other parkinsonian syndromes in which the levodopa response pattern is typical of PD.
Chou
Kelvin L
KL
Parkinson's Disease and Movement Disorders Center and Department of Neurosurgery, Penn Neurological Institute at Pennsylvania Hospital, Philadelphia, Pennsylvania 19107, USA.
Forman
Mark S
MS
Trojanowski
John Q
JQ
Hurtig
Howard I
HI
Baltuch
Gordon H
GH
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001479:Basal Ganglia / Q000473:pathology; D001933:Brain Stem / Q000473:pathology; D002531:Cerebellum / Q000473:pathology; D003937:Diagnosis, Differential; D004599:Electric Stimulation Therapy / Q000295:instrumentation; D017809:Fatal Outcome; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D013378:Substantia Nigra / Q000473:pathology; D020531:Subthalamic Nucleus / Q000502:physiology*
D000978:Antiparkinson Agents; D007980:Levodopa